Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Inclusion Criteria

• •Age 18 or older
• •Patients whose tumor is determined to be unmethylated
• •Patients with incomplete resection as determined by residual, measurable gadolinium or contrast-enhancing lesion or lesions
• •Recent resection of glioblastoma within 4 weeks of study entry. Patients who have only had a tumor biopsy and who are considered unresectable are eligible (but based on the study accrual this subset of patients with unresectable tumor may be considered for separate analysis)
• •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤ 2 (see appendix A)
• •Willing to remain abstinent from consuming alcohol while on DSF
• •No prior radiation or chemotherapy
• •Meets the following laboratory criteria:
• •* Absolute neutrophil count ≥ 1,500/mcL (microliter)
• •* Platelets ≥ 100,000/mcL
• •* Hemoglobin \> 10.0 g/dL (grams/deciliter) (transfusion and/or ESA (erythropoiesis-stimulating agent) allowed)
• •* Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN)
• •* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN
• •* Blood urea nitrogen (BUN) and creatinine \< 1.5 x ULN
• •Able to take oral medication
• •Able to understand and willing to sign an institutional review board (IRB)-approved written informed consent document (legally authorized representative permitted)